LEVOTIROXINA ACCORD 175 micrograme Rumunjska - rumunjski - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levotiroxina accord 175 micrograme

laboratori fundacio dau - spania - levothyroxinum - compr. - 175micrograme - preparate de tiroida hormoni tiroidieni

LEVOTIROXINA ACCORD 200 micrograme Rumunjska - rumunjski - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levotiroxina accord 200 micrograme

laboratori fundacio dau - spania - levothyroxinum - compr. - 200micrograme - preparate de tiroida hormoni tiroidieni

LEVOTIROXINA ACCORD 25 micrograme Rumunjska - rumunjski - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levotiroxina accord 25 micrograme

laboratori fundacio dau - spania - levothyroxinum - compr. - 25micrograme - preparate de tiroida hormoni tiroidieni

LEVOTIROXINA ACCORD 50 micrograme Rumunjska - rumunjski - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levotiroxina accord 50 micrograme

laboratori fundacio dau - spania - levothyroxinum - compr. - 50micrograme - preparate de tiroida hormoni tiroidieni

LEVOTIROXINA ACCORD 75 micrograme Rumunjska - rumunjski - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levotiroxina accord 75 micrograme

laboratori fundacio dau - spania - levothyroxinum - compr. - 75micrograme - preparate de tiroida hormoni tiroidieni

LEVOTIROXINA ACCORD 88 micrograme Rumunjska - rumunjski - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levotiroxina accord 88 micrograme

laboratori fundacio dau - spania - levothyroxinum - compr. - 88micrograme - preparate de tiroida hormoni tiroidieni

Qinlock Europska Unija - rumunjski - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumorile stromale gastro-intestinale - agenți antineoplazici - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.